Psychedelic Drugs Market: By Drugs, 3,4-MethylEnedioxyMethamphetamine, Phencyclidine, Gamma Hydroxybutyric Acid, Etamine, Ayahuasca, Salvia, Psilocybin, Others), By Application, By End User and Region Forecast 2019-2030
Psychedelic Drugs Market size was valued at US$ 553.9 million in 2023 and is poised to grow at a significant CAGR of 38.8% from 2024-2030. Psychedelic drugs enhance or change sensory perceptions, energy levels, cognitive processes, and spiritual experiences. Psychedelic drugs are classified into dissociative medications (such as phencyclidine), empathogens, and serotonergic drugs (such as lysergic acid diethylamide). These drugs treat many conditions, including major depression, treatment-resistant depression, panic disorder, post-traumatic stress disorder, and opiate addiction. Based on the end user, the psychedelic drug market is segmented into Hospitals, Homecare, Specialty Clinics, and Others.
The hospital/pharmacy segment is anticipated to grow at a significant CAGR over the forecast years, During the COVID-19 pandemic, demand for psychedelic drugs increased as hospital pharmacies were overburdened with treating patients' mental health disorders, boosting segment growth even further. The growing global awareness of people's mental health and the use of psychedelic drugs for specific indications is driving the growth of hospital pharmacies as a distribution channel. The anti-inflammatory activity of psychedelic drugs has also contributed to the market's growth. Growing acceptance of psychedelic drugs for treating depression, increasing prevalence of depression and mental disorders, rising awareness of mental health, and growing r&d activities in psychedelic drugs are a few factors driving the industry's growth over the forecasting period.
Study Period
2024-2030Base Year
2023CAGR
38.8%Largest Market
North AmericaFastest Growing Market
Asia Pacific
Psychedelics have grown in popularity in the last decade because they are used in human mental healing and treatment practices and can heal the mind. Researchers and scientists are investigating the therapeutic value of psychedelic drugs and compounds that could be a new treatment option for people suffering from depression. Continuous research and development in psychedelic drugs have increased the medication's acceptance. Psychedelic drugs' promising outcomes have increased their use in the United States and other regions, resulting in rising demand for psychedelic drugs; thus, these factors are expected to act as market drivers.
The Psychedelic Drugs market in North America is likely to hold the highest revenue share in 2022, and the same trend is expected over the forecast period. Because of the increase in mental illness and the prevalence and incidence of mental disorder problems, North America held a significant market share for psychedelic drugs in 2020. This trend is expected to continue during the forecast period. In the United States, severe mental health disorders such as depression, stress, and obsessive-compulsive disorders are also high. According to the National Institute of Mental Health (NIMH), an estimated 52.9 million adults aged 18 and older in the United States had a mental illness in 2020. The report also stated that females had a higher rate of mental illness than males, at 25.8%. Further, Asia Pacific held the highest CAGR during forecast period.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 553.9 million |
|
Market CAGR |
38.8% |
|
By Drugs |
|
|
By Application |
|
|
By End User |
|
|
By Region |
|
Download Free Sample Report
The psychedelic drugs market size was valued at US$ 553.9 million in 2023 and is poised to grow at a significant CAGR of 38.8% from 2024-2030.
The market's key players are: Roche Holding AG Pfizer Inc. The Emmes Company COMPASS Group plc Merck & Co. Inc. AstraZeneca PLC AbbVie Inc. Mylan N.V. Alkermes plc Dr. Reddy’s Laboratories
The market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
| 1. Executive Summary |
| 2. Global Psychedelic Drugs Market Introduction |
| 2.1.Global Psychedelic Drugs Market - Taxonomy |
| 2.2.Global Psychedelic Drugs Market - Definitions |
| 2.2.1.Drugs |
| 2.2.2.Application |
| 2.2.3.End User |
| 2.2.4.Geography |
| 2.2.5.Region |
| 3. Global Psychedelic Drugs Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Psychedelic Drugs Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Psychedelic Drugs Market By Drugs, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Lysergic Acid Diethylamide (LSD) |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. 3,4-MethylEnedioxyMethamphetamine (Ecstasy) |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Phencyclidine |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Gamma Hydroxybutyric Acid (GHB) |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Etamine |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Ayahuasca |
| 5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. Salvia |
| 5.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.7.3. Market Opportunity Analysis |
| 5.8. Psilocybin |
| 5.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.8.3. Market Opportunity Analysis |
| 5.9. Others |
| 5.9.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.9.3. Market Opportunity Analysis |
| 6. Global Psychedelic Drugs Market By Application, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Resistant depression |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Panic disorder |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Post-traumatic stress disorder |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Opiate Addiction |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Others |
| 6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 7. Global Psychedelic Drugs Market By End User , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Hospitals |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Homecare |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Specialty Clinics |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Others |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 8. Global Psychedelic Drugs Market By Geography, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. The Asia Pacific |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Latin America |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. MEA |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9. Global Psychedelic Drugs Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia Pacific (APAC) |
| 9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Middle East and Africa (MEA) |
| 9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Latin America |
| 9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 10. North America Psychedelic Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Drugs Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Lysergic Acid Diethylamide (LSD) |
| 10.1.2.3,4-MethylEnedioxyMethamphetamine (Ecstasy) |
| 10.1.3.Phencyclidine |
| 10.1.4.Gamma Hydroxybutyric Acid (GHB) |
| 10.1.5.Etamine |
| 10.1.6.Ayahuasca |
| 10.1.7.Salvia |
| 10.1.8.Psilocybin |
| 10.1.9.Others |
| 10.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Resistant depression |
| 10.2.2.Panic disorder |
| 10.2.3.Post-traumatic stress disorder |
| 10.2.4.Opiate Addiction |
| 10.2.5.Others |
| 10.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospitals |
| 10.3.2.Homecare |
| 10.3.3.Specialty Clinics |
| 10.3.4.Others |
| 10.4. Geography Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.North America |
| 10.4.2.Europe |
| 10.4.3.The Asia Pacific |
| 10.4.4.Latin America |
| 10.4.5.MEA |
| 10.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.5.1.United States of America (USA) |
| 10.5.2.Canada |
| 11. Europe Psychedelic Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Drugs Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Lysergic Acid Diethylamide (LSD) |
| 11.1.2.3,4-MethylEnedioxyMethamphetamine (Ecstasy) |
| 11.1.3.Phencyclidine |
| 11.1.4.Gamma Hydroxybutyric Acid (GHB) |
| 11.1.5.Etamine |
| 11.1.6.Ayahuasca |
| 11.1.7.Salvia |
| 11.1.8.Psilocybin |
| 11.1.9.Others |
| 11.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Resistant depression |
| 11.2.2.Panic disorder |
| 11.2.3.Post-traumatic stress disorder |
| 11.2.4.Opiate Addiction |
| 11.2.5.Others |
| 11.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospitals |
| 11.3.2.Homecare |
| 11.3.3.Specialty Clinics |
| 11.3.4.Others |
| 11.4. Geography Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.North America |
| 11.4.2.Europe |
| 11.4.3.The Asia Pacific |
| 11.4.4.Latin America |
| 11.4.5.MEA |
| 11.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.5.1.Germany |
| 11.5.2.France |
| 11.5.3.Italy |
| 11.5.4.United Kingdom (UK) |
| 11.5.5.Spain |
| 11.5.6.Rest of EU |
| 12. Asia Pacific (APAC) Psychedelic Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Drugs Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Lysergic Acid Diethylamide (LSD) |
| 12.1.2.3,4-MethylEnedioxyMethamphetamine (Ecstasy) |
| 12.1.3.Phencyclidine |
| 12.1.4.Gamma Hydroxybutyric Acid (GHB) |
| 12.1.5.Etamine |
| 12.1.6.Ayahuasca |
| 12.1.7.Salvia |
| 12.1.8.Psilocybin |
| 12.1.9.Others |
| 12.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Resistant depression |
| 12.2.2.Panic disorder |
| 12.2.3.Post-traumatic stress disorder |
| 12.2.4.Opiate Addiction |
| 12.2.5.Others |
| 12.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospitals |
| 12.3.2.Homecare |
| 12.3.3.Specialty Clinics |
| 12.3.4.Others |
| 12.4. Geography Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.North America |
| 12.4.2.Europe |
| 12.4.3.The Asia Pacific |
| 12.4.4.Latin America |
| 12.4.5.MEA |
| 12.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.5.1.China |
| 12.5.2.India |
| 12.5.3.Australia and New Zealand (ANZ) |
| 12.5.4.Japan |
| 12.5.5.Rest of APAC |
| 13. Middle East and Africa (MEA) Psychedelic Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Drugs Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Lysergic Acid Diethylamide (LSD) |
| 13.1.2.3,4-MethylEnedioxyMethamphetamine (Ecstasy) |
| 13.1.3.Phencyclidine |
| 13.1.4.Gamma Hydroxybutyric Acid (GHB) |
| 13.1.5.Etamine |
| 13.1.6.Ayahuasca |
| 13.1.7.Salvia |
| 13.1.8.Psilocybin |
| 13.1.9.Others |
| 13.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Resistant depression |
| 13.2.2.Panic disorder |
| 13.2.3.Post-traumatic stress disorder |
| 13.2.4.Opiate Addiction |
| 13.2.5.Others |
| 13.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospitals |
| 13.3.2.Homecare |
| 13.3.3.Specialty Clinics |
| 13.3.4.Others |
| 13.4. Geography Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.North America |
| 13.4.2.Europe |
| 13.4.3.The Asia Pacific |
| 13.4.4.Latin America |
| 13.4.5.MEA |
| 13.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.5.1.GCC Countries |
| 13.5.2.South Africa |
| 13.5.3.Rest of MEA |
| 14. Latin America Psychedelic Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 14.1. Drugs Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1.Lysergic Acid Diethylamide (LSD) |
| 14.1.2.3,4-MethylEnedioxyMethamphetamine (Ecstasy) |
| 14.1.3.Phencyclidine |
| 14.1.4.Gamma Hydroxybutyric Acid (GHB) |
| 14.1.5.Etamine |
| 14.1.6.Ayahuasca |
| 14.1.7.Salvia |
| 14.1.8.Psilocybin |
| 14.1.9.Others |
| 14.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1.Resistant depression |
| 14.2.2.Panic disorder |
| 14.2.3.Post-traumatic stress disorder |
| 14.2.4.Opiate Addiction |
| 14.2.5.Others |
| 14.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.3.1.Hospitals |
| 14.3.2.Homecare |
| 14.3.3.Specialty Clinics |
| 14.3.4.Others |
| 14.4. Geography Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.4.1.North America |
| 14.4.2.Europe |
| 14.4.3.The Asia Pacific |
| 14.4.4.Latin America |
| 14.4.5.MEA |
| 14.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.5.1.Brazil |
| 14.5.2.Mexico |
| 14.5.3.Rest of LA |
| 15. Competition Landscape |
| 15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 15.2.1.Roche Holding AG |
| 15.2.2.Pfizer Inc. |
| 15.2.3.The Emmes Company |
| 15.2.4.COMPASS Group plc |
| 15.2.5.Merck & Co. Inc. |
| 15.2.6.AstraZeneca PLC |
| 15.2.7.AbbVie Inc. |
| 15.2.8.Mylan N.V. |
| 15.2.9.Alkermes plc |
| 15.2.10.Dr. Reddy’s Laboratories |
| 16. Research Methodology |
| 17. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Free Sample
